Skin appearance and recovery
Community
Community blend positioning; no clinical combination benefit has been demonstrated.2
Skin & recoveryBlend
GLOW
GHK-Cu, BPC-157, and TB-500 blend
No FDA-approved GLOW blend; compositions and TB-500 identity can vary.
What does it do?
Inflammation
Community
Claims about combined effects remain untested for this named mixture.2
Molecular information
1Amino-acid sequence
This blend contains multiple compounds and has no single amino-acid sequence.
GHK-Cu50 mgBPC-15710 mgTB-500 (label)10 mg
LengthMultiple peptides
Molecular weight · DaNo single molecular weight
Molecular formulaNo single molecular formula1
Example: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (70 mg total). Ratios and TB-500 identity require product-specific verification.
Pharmacokinetics
There is no single half-life for a mixture. Component kinetics cannot be averaged into a validated blend curve, and no human combination PK study is cited.
What to expect
Study outcomes
Reported timelines
Reference & communityNo validated blend timeline
Effects depend on formulation and individual ingredients; synergy unproven.7
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | Calculate individual peptide amounts | Based on component requirements | Conservative ApproachReference report | Monitor individual peptide accumulation | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility labels do not establish safety. Individual components permit clearer exposure tracking; no validated universal therapeutic ranges exist for this blend. Source tabs Injectable | |||||
| SubQ | Per supplier guidelines | As recommended | Standard ProtocolReference report | Monitor individual peptide accumulation | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility labels do not establish safety. Individual components permit clearer exposure tracking; no validated universal therapeutic ranges exist for this blend. Source tabs Injectable | |||||
| OtherMultiple injections | Separate peptides | Optimized schedules | Individual Peptide AlternativeReference report | Monitor individual peptide accumulation | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility labels do not establish safety. Individual components permit clearer exposure tracking; no validated universal therapeutic ranges exist for this blend. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Monitor individual peptide accumulation
- Break
- Based on component peptide requirements
Reported timing
Consistent timing preferred
Side effects & safety
Combination safety gap
Individual-component research cannot establish safety of the mixture.
2Identity and amount uncertainty
The trade name alone is insufficient to identify component quantities or the TB-500 molecular form.
1Attribution is difficult
With multiple components, a perceived benefit or adverse effect cannot readily be assigned to one ingredient.
2Fixed ratios
Total blend mass conceals different component exposures; copper accumulation and intolerance matter.
Stop symptoms
Persistent discoloration, nausea/headache or systemic symptoms, worsening injection reactions or allergy.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Retinoids
Caution reportedSkin irritation concern.7
Reference report · Pep-Pedia label: Use CautionAHA/BHA
Caution reportedSource flags sensitivity; exact safe interval unestablished.7
Reference report · Pep-Pedia label: Requires TimingIndividual GHK-Cu
Avoidance reportedDuplicate copper exposure.7
Reference report · Pep-Pedia label: Avoid CombinationIndividual BPC-157
Caution reportedDuplicate peptide exposure.7
Reference report · Pep-Pedia label: Monitor CombinationNAD+
Unverified pairingTheoretical cellular-energy complement.7
Reference report · Pep-Pedia label: CompatibleVitamin C
Unverified pairingProposed antioxidant complement.7
Reference report · Pep-Pedia label: CompatibleThe components with one another
Not establishedNo controlled human study of this named formulation establishes compatibility, synergy or interaction risk.21
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
A total-mg label alone cannot determine the preparation or amount of each component.1
Composition first
Example: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (70 mg total).1
No universal diluent or storage rule
The cited listing does not validate a BAC-water volume, combined chemical stability, sterility after preparation, or multidose beyond-use date.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia requires component amounts to be checked before calculating blend concentration.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Its labels include preparation date, volume and each component concentration. · Reported storage: 2–8°C for 28 days.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceBlue SolutionReported variationVerify Peptide ContentReported concernExcessive Individual Peptide AmountsReported appearanceProper PackagingReported variationCopper Discoloration
7Vial sizes
70mg1
- GHK-Cu
- 50 mg
- BPC-157
- 10 mg
- TB-500 (label)
- 10 mg
Amounts are total blend mass. Formulas and ratios vary. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Evidence limits
View findings →Efficacy, stability, compatibility, and safety of the exact combined formulation.1
0 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
No blend trialsSource context
Source compatibility labels do not establish safety. Individual components permit clearer exposure tracking; no validated universal therapeutic ranges exist for this blend.
Compound identity & other names
A market name commonly used for GHK-Cu, BPC-157, and a product labeled TB-500. It is not a standardized drug. Individual-component research cannot establish that combining them improves results or is safe.
Other names: Glow blend · Glow protocol · GHK-Cu BPC-157 TB-500 · GLOW 70 · Glow Protocol
No FDA-approved GLOW blend; compositions and TB-500 identity can vary.
GLOW is a mixture, not a single molecule1
How it may work
Combines proposed collagen, inflammatory, cell-migration and vascular pathways; ingredient mechanisms do not prove synergy.7
Labeled blend composition
One checked catalog lists 50 mg GHK-Cu plus 10 mg BPC-157 and 10 mg TB-500, totaling 70 mg. This is a supplier specification, not clinical evidence.
1No exact-blend clinical result verified
No controlled study of this exact three-component vial was identified in the reviewed sources. Pep-Pedia itself describes limited combination evidence.
2Research areas and evidence gaps
- Efficacy, stability, compatibility, and safety of the exact combined formulation.
- Whether any claimed benefit comes from a component, co-treatment, placebo, or natural change.
- The sequence of material labeled TB-500 and the actual per-component quantities.
Additional uses listed by Pep-Pedia
Skin and collagen. Rejuvenation, elasticity and aging claims extrapolated from components.7
Tissue recovery. Wound, procedure and injury-repair claims.7
Cellular protection. Antioxidant/remodeling hypotheses.7
Community reports Unvalidated
GLOW is discussed for skin appearance and recovery. The reference page describes variable formulations rather than a uniform regimen.2
These are secondary descriptions. The blend name alone cannot determine component amounts, stability, or effects.
Search coverage and review status
No direct controlled trial of this named blend was identified in the targeted check. Component literature is retained separately from blend claims.
- Checked
- 2026-10-12
- Search
- GLOW BPC-157 GHK trial study
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 15 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 25 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 16 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 15 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “2442 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1FSD Bio Labs GLOW 70 mg compositionComponent research or community information does not establish effects of this blend.Catalog checked
AI-PREPARED SUMMARY
Lists a 50:10:10 mg GHK-Cu/BPC-157/TB-500 blend. A manufacturer label supports the nominal composition only, not safety, synergy, or measured batch content.
Labeled blend composition
One checked catalog lists 50 mg GHK-Cu plus 10 mg BPC-157 and 10 mg TB-500, totaling 70 mg. This is a supplier specification, not clinical evidence.
2Pep-Pedia: glow community protocol referenceComponent research or community information does not establish effects of this blend.Community source checked
AI-PREPARED SUMMARY
Describes a three-peptide combination, variable schedules, and limited formal combination evidence. Its component research does not test the blend itself.
No exact-blend clinical result verified
No controlled study of this exact three-component vial was identified in the reviewed sources. Pep-Pedia itself describes limited combination evidence.
3BPC-157 Tissue Repair Mechanisms (2024)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The card invokes BPC-157 tissue-repair experiments but appends a human-like dose range without an identifiable linked trial; GLOW itself was not tested.
Reported population / model
Laboratory Study
Reported study details
Individual Peptide · Multiple Studies · Dose range 250-500mcg daily
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4TB-500 Angiogenesis Studies (2024)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The card associates animal tissue-repair findings with a twice-weekly milligram schedule; that schedule and a GLOW benefit are not validated by the card.
Reported population / model
Preclinical Research
Reported study details
Individual Peptide · Animal Models · 2-5mg twice weekly
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Combination Peptide Protocols: Limited Data (2024)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source acknowledges a lack of controlled evidence for fixed-ratio blends; experience-based protocols cannot establish combination efficacy.
Reported population / model
Review Study
Reported study details
Combination Therapy · Clinical Observation · Variable dosing
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6GHK-Cu Anti-Aging Research (2023)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The card claims skin benefits at daily injectable milligram doses without a primary-study link; topical GHK-Cu findings cannot validate that regimen.
Reported population / model
Clinical Studies
Reported study details
Individual Peptide · Various Trials · Effective dose 1-2mg daily
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Pep-Pedia: GLOW — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12